Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.22 (
cdc2
)
8,319
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
B-MYB
expression is associated with cell proliferation and recent studies have suggested that it promotes the S phase of mammalian cells. Based on its homology to the transcription factors c-MYB and A-MYB,
B-MYB
is thought to be involved in transcriptional regulation; however, its activity is not detectable in several cell lines. It was postulated that
B-MYB
function may depend on the presence of a cofactor, and recent studies suggested that
B-MYB
is phosphorylated specifically during S phase in murine fibroblasts. In this report we provide evidence that the product of the human B-myb gene can be activated in vivo by coexpression with cyclin A or cyclin E. Transfection studies showed that
B-MYB
was a weak transcriptional activator in SAOS-2 cells and was unable to promote their proliferation. In contrast, overexpression of both
B-MYB
and cyclin A or cyclin E caused a drastic increase in the number of SAOS-2 cells in S phase. Also, overexpression of cyclin A and cyclin E in SAOS-2 cells enhanced the ability of
B-MYB
, but not c-MYB, to transactivate various promoters, including the
cdc2
promoter, the HIV-1-LTR, and the simian virus 40 minimal promoter. A direct role for cyclin-dependent activation of
B-MYB
was demonstrated using an in vitro transcription assay. These observations suggest that one mechanism by which cyclin A and E may promote the S phase is through modification and activation of
B-MYB
.
...
PMID:Activation of human B-MYB by cyclins. 901 18
PARP is a multifunctional protein that can affect genome stability, transcription control, telomere length and cell death. Recently we have reported that PARP binds to and enhances
B-MYB
transactivating potential.
B-MYB
is a potentially oncogenic transcription factor involved in mammalian cell proliferation, survival and differentiation.
B-MYB
gene expression is growth regulated and
B-MYB
protein is phosphorylated during S phase by cyclin A or E/
cdk2
kinase, resulting in augmented transactivating potential. Here we show that PARP induces phosphorylation of
B-MYB
protein at
cdk2
phosphorylation sites, since a
B-MYB
protein with mutated
cdk2
phosphorylation sites is refractory to PARP-induced phosphorylation and co-activation in mammalian cells. We propose that PARP functions as a
B-MYB
co-factor by promoting cyclin/
cdk2
-dependent
B-MYB
phosphorylation. These results highlight a novel role for PARP as a factor that integrates cyclin-dependent kinases signaling with gene transcription.
...
PMID:PARP co-activates B-MYB through enhanced phosphorylation at cyclin/cdk2 sites. 1178 32
Recently, the conserved human LINC/DREAM complex has been described as an important regulator of cell cycle genes. LINC consists of a core module that dynamically associates with E2F transcription factors, p130 and the
B-MYB
transcription factor in a cell cycle-dependent manner. In this study, we analyzed the evolutionary conserved LIN54 subunit of LINC. We found that LIN54 is required for cell cycle progression. Protein interaction studies demonstrated that a predicted helix-coil-helix motif is required for the interaction of LIN54 with p130 and
B-MYB
. In addition, we found that the cysteine-rich CXC domain of LIN54 is a novel DNA-binding domain that binds to the
cdc2
promoter in a sequence-specific manner. We identified two binding sites for LIN54 in the
cdc2
promoter, one of which overlaps with the cell cycle homology region at the transcriptional start site. Gel shift assays suggested that, in quiescent cells, the binding of LIN54 at the cell cycle homology region is stabilized by the binding of E2F4 to the adjacent cell cycle-dependent element. Our data demonstrate that LIN54 is an important and integral subunit of LINC.
...
PMID:LIN54 is an essential core subunit of the DREAM/LINC complex that binds to the cdc2 promoter in a sequence-specific manner. 1972 79